RxDoctor Payments Data

David Steiner, MD

Psychiatry · Augusta, GANPI 1972508802

Payments from drug & device makers

$8,743in general payments, 2019–2025

Across 478 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$856
  • Neurocrine Biosciences, Inc.$855
  • Takeda Pharmaceuticals U.S.A., Inc.$687
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$647
  • Teva Pharmaceuticals USA, Inc.$631
  • plus $4K from 29 others

What the payments were for

  • Food & beverage$8,59798%
  • Education$1462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,743 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$103,599
Medicare patients
382
Services billed
1,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl98$151,616
Invega SustennaPaliperidone Palmitate20$64,869
RexultiBrexpiprazole26$51,646
CaplytaLumateperone Tosylate23$39,666
TrintellixVortioxetine Hydrobromide55$33,277
AuvelityDextromethorphan Hbr/Bupropion23$27,386
BelsomraSuvorexant40$25,517
Quetiapine Fumarate654$20,811
Aripiprazole429$18,931
Divalproex Sodium ErDivalproex Sodium261$14,666
Oxcarbazepine262$14,461
VyvanseLisdexamfetamine Dimesylate27$14,236
Paliperidone ErPaliperidone73$13,252
Bupropion XlBupropion Hcl604$11,927
Olanzapine382$10,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,400$151,61698 claims
Johnson & JohnsonInvega Sustenna$204$64,86920 claims
Otsuka America Pharmaceutical, Inc.Rexulti$856$51,64626 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$687$47,51382 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$647$39,66623 claims
Axsome Therapeutics, Inc.Auvelity$285$27,38623 claims
MerckBelsomra$198$25,51740 claims
Lilly USA, LLCOlanzapine$39$10,832382 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →